Compare KREF & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KREF | ALT |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.8M | 421.5M |
| IPO Year | N/A | 2005 |
| Metric | KREF | ALT |
|---|---|---|
| Price | $6.70 | $3.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $9.58 | ★ $17.67 |
| AVG Volume (30 Days) | 1.3M | ★ 2.6M |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 15.18% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $545.92 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $5.87 | $2.87 |
| 52 Week High | $9.98 | $7.73 |
| Indicator | KREF | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 56.40 | 46.77 |
| Support Level | $6.64 | $2.87 |
| Resistance Level | $7.50 | $4.25 |
| Average True Range (ATR) | 0.19 | 0.16 |
| MACD | 0.09 | 0.06 |
| Stochastic Oscillator | 99.40 | 76.87 |
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.